http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference
-
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference
-
WAVE Life Sciences (WVE) Reports Positive Update from Phase 1b/2a SELECT-HD Trial
-
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease
-
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease
-
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
-
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
-
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022
-
Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022
-
Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
-
Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
-
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
-
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
-
Wave Life Sciences to Present at Upcoming Investor Conferences
-
Wave Life Sciences to Present at Upcoming Investor Conferences
-
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022
-
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022
-
WAVE Life Sciences (WVE) Reports Publication of Foundational Preclinical Data Supporting Development of WVE-004
-
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD
-
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD
-
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
WAVE Life Sciences (WVE) Reports Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study
-
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004
-
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004
-
Wave Life Sciences to Present at Stifel 2022 CNS Days
-
Wave Life Sciences to Present at Stifel 2022 CNS Days
-
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors
-
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors
-
Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings
-
Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings
-
WAVE Life Sciences (WVE) Reports Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme
-
WAVE Life Sciences (WVE) Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme
-
Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme
-
Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
-
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
-
Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
-
Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
-
Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides
-
Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides
-
ADDF and AFTD Partner to Support Wave Life Sciences' FTD and ALS Clinical Program
-
Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference
-
Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference
